Quest Diagnostics Aktie
WKN: 904533 / ISIN: US74834L1008
22.07.2025 20:19:56
|
Quest Diagnostics Boosts Its 2025 Outlook
Quest Diagnostics (NYSE:DGX) reported its second-quarter 2025 results on July 22, achieving consolidated revenue of $2.76 billion (up 15.2% year over year), organic revenue growth of 5.2%, while adjusted EPS rose 11.5% year over year to $2.62. Management raised full-year revenue guidance to $10.8 billion to $10.92 billion and adjusted EPS to $9.63 to $9.83, citing sustained demand for advanced diagnostics, the integration of last year's LifeLabs acquisition, and scale-driven productivity gains. Investors should note updated mid-term expectations for growth drivers, operational efficiencies, and regulatory risk exposure discussed below.Reported operating income increased to $438 million and adjusted operating income was $466 million, expanding margins by 110 basis points and 30 basis points year over year, respectively, reflecting strategic automation deployments. Cash from operations surged 67.1% year to date to $858 million, aided by a one-time CARES Act tax credit and the timing of receipts and disbursements.Systematic automation rollouts underpin the company’s targeted 3% annual cost and productivity improvement forecast.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Quest Diagnostics Inc.mehr Nachrichten
Analysen zu Quest Diagnostics Inc.mehr Analysen
Aktien in diesem Artikel
Quest Diagnostics Inc. | 151,90 | 7,27% |
|